In this retrospective study of Taiwanese women using antipsychotic medications there was no observed increase in risk of metabolic complications.
This meta-analysis is reassuring regarding risk for malformations in children exposed prenatally to oxcarbazepine; however, we still need more data to fully assess reproductive safety.
Data from a Nordic register-based study observed a significant increase in risk for autism spectrum disorder and intellectual disability in children with prenatal exposure to topiramate.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.
The use of valproic acid during pregnancy is associated with a significant increase in risk of major malformations and neurodevelopmental disorders. Given these risks, should it be a treatment option for women of childbearing age?
Largest Study Ever Shows No Increase in Risk of Neurodevelopmental Disorders in Kids Exposed to Antidepressants In Utero
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
A recent study shows the OCRDs, especially those that are more body-focused, have the potential to emerge or worsen during pregnancy and the postpartum, leading to high levels of comorbid depression and functional impairment.
Despite the unequivocal benefits of folic acid supplementation and recommendations urging all women of reproductive age to take folic acid supplements, preconceptual use of folic acid has not increased substantially.
Moving Backwards? Why Doesn’t the Canadian Task Force on Preventive Health Care Recommend Standardized Screening for Perinatal Depression?
This task force does not recommend universal, instrument-based screening for perinatal depression because we lack clear evidence that screening improves outcomes.
Accumulating Data on the Reproductive Safety of Second-Generation Antipsychotics, But Still Not Enough
In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.